Trial Profile

A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients With Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor Therapy

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 19 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Copanlisib (Primary) ; Olaparib (Primary) ; Doxorubicin liposomal; Paclitaxel; Topotecan
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use

14 Jul 2023 Status changed from suspended to withdrawn prior to enrolment due to drug supply issue.
14 Jul 2023 Planned End Date changed from 30 Jul 2024 to 17 Mar 2023.
14 Jul 2023 Planned primary completion date changed from 30 Jul 2024 to 17 Mar 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com